Navigation Links
Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan

iology and Hypertension Program and Professor of Medicine at the University of Alabama at Birmingham in Alabama. "In addition to important blood pressure lowering, the combination of Tekturna and Diovan maintained a tolerability profile similar to that seen with either agent alone," said Dr. Oparil.

Tekturna received U.S. regulatory approval for treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. In an extensive clinical trial program involving more than 6,400 patients, Tekturna provided significant blood pressure reductions for a full 24 hours. This once-daily oral therapy is expected to be available by the end of March in U.S. pharmacies as 150 mg and 300 mg tablets.

A second study presented at the meeting compared Tekturna (150 mg or 300 mg alone or 300 mg in combination with HCTZ) to ramipril (5 mg or 10 mg alone or 10 mg in combination with HCTZ), another high blood pressure medicine in a class known as angiotensin converting enzyme (ACE) inhibitors (ACC presentation #1014). Results showed 61.4% of patients treated with the Tekturna-based therapy reached their blood pressure goal vs. 53.1% of patients treated with the ramipril-based therapy.

Tekturna and Diovan should be discontinued as soon as pregnancy is detected as they may harm an unborn baby, causing injury and even death. Women who plan to become pregnant should talk to their doctor about other treatment options before taking Tekturna or Diovan.

The need for new high blood pressure medicines is urgent given that this condition affects one in three adults in the U.S. and nearly 70% of these patients remain uncontrolled. In fact, many require two or more medications to reach their target blood pressure goal. Uncontrolled high blood pressure can increase the risk of cardiovascular disease, the world's leading cause of death.

"We are very encouraged by these results since they show Tekturna and Diovan are effective w
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/4/2015)... BEIJING , Aug. 4, 2015 Concord Medical ... a leading specialty hospital management solution provider and operator of ... China , today announced it will release ... the market closes on August 17, 2015. Management ... following day, at 8:00 a.m. EDT on August 18, 2015 ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, today ... will present live at VirtualInvestorConferences.com on August 6, ... TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... online event where investors are invited to ask ...
Breaking Medicine Technology:Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
... , May 10 Ferring Pharmaceuticals ... Women,s Health product portfolio with the acquisition of ... acid), a first-in-class, non-hormonal therapy indicated specifically for ... (HMB).  The company will initially market LYSTEDA in ...
... 10 Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced the ... Mr. Macaluso replaces Dr. David Bar-Or, who remains the Chief Scientific Officer and ... Bar-Or have served on Ampio,s Board since the date of its acquisition of ... , , ...
Cached Medicine Technology:Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 2Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 3Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 4Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 5Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer 2
(Date:8/4/2015)... ... 04, 2015 , ... assistPoint Partners, LLC is proud ... patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, Patients ... level, cloud-based application and workflow solution. This provides cancer center patient advocates, financial ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces ... to fit, for example, on hard hats that have a flip-up face shield. The ... allows users to work without having to remove their headlamp when raising or lowering ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Worldwide Power Products is expanding its reach in Texas. Effective July 1st of ... Systems North Texas generator division. With the North Texas acquisition, Worldwide Power ...
(Date:8/4/2015)... , ... August 04, 2015 , ... One of the ... to discuss his new book, The Pain Antidote , which provides strategies for ... Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction with ...
Breaking Medicine News(10 mins):Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... hospitals , , MONDAY, Dec. 17 (HealthDay News) -- A ... and anxiety that often follows major surgery, new research ... was equivalent to a [dose] of morphine, which was ... Hinshaw, professor of surgery and a member of the ...
... NEW MARTINSVILLE, W.Va., Dec. 17 In ... become tomorrow,s environmental,stewards, Bayer Corporation and the ... (UNEP RONA) today announced a new World,Environment ... Competition in Bayer MaterialScience New Martinsville partner,schools., ...
... OWINGS MILLS, Md., Dec. 17 Medifast, Inc.,(NYSE: ... has received approval to sell,Medifast Weight Control Centers ... available in 43 states. Medifast recently,received approval to ... Rhode Island and Virginia., "The Medifast Weight ...
... season is a,great opportunity to relax, spend time with family, ... the next 12 months. These top resolutions,offered by the American ... healthy new you in 2008., "Creating and sticking to ... you can give yourself this holiday season," said AMA,President, Ron ...
... a high volume of corrective surgeries show higher survival ... -- Babies with congenital heart defects are more likely ... the most experience in treating such cases, U.S. researchers ... figures from the 2003 Kids, Inpatient Database, which is ...
... Murtha, Chairman of the House Appropriations Subcommittee on Defense, this ... veterans blinded by war and for research to restore their ... gives the Man of Vision Award to an individual who ... of the challenges of vision loss. Among previous awardees have ...
Cached Medicine News:Health News:Massage Eases Pain, Anxiety After Surgery 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 4Health News:Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States 2Health News:AMA: Resolutions for a Healthy New You in the New Year 2Health News:Babies With Heart Defects Do Best at Hospitals With Most Experience 2Health News:Champion of blinded soldiers, Congressman Murtha, is Man of Vision 2
MD Coder v 6.0 is a charge capture for the Palm OS and Pocket PC operating systems. We have integrated the feedback from hospitals and physicians. MD Coder v 6.0 comes in three versions: Physician Ba...
ZapICD is a reference to the complete set of ICD codes....
... Care Manager is an electronic ... and data management of wounds ... was developed using industry expert ... with the most current assessment ...
... Integrated patient tracking ... contains the complete Handheld ... application, and complete CPT™ ... from the AMA. Designed ...
Medicine Products: